0001209191-13-057504.txt : 20131217 0001209191-13-057504.hdr.sgml : 20131217 20131217175354 ACCESSION NUMBER: 0001209191-13-057504 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20131216 FILED AS OF DATE: 20131217 DATE AS OF CHANGE: 20131217 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Epizyme, Inc. CENTRAL INDEX KEY: 0001571498 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261349956 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 TECHNOLOGY SQUARE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-229-5872 MAIL ADDRESS: STREET 1: 400 TECHNOLOGY SQUARE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Copeland Robert A CENTRAL INDEX KEY: 0001577021 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35945 FILM NUMBER: 131283263 MAIL ADDRESS: STREET 1: C/O EPIZYME, INC. STREET 2: 400 TECHNOLOGY SQUARE, 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2013-12-16 0 0001571498 Epizyme, Inc. EPZM 0001577021 Copeland Robert A C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 0 1 0 0 EVP and CSO Common Stock, par value $0.0001 per share 2013-12-16 4 M 0 4600 2.19 A 58144 D Common Stock, par value $0.0001 per share 2013-12-16 4 S 0 4600 21.2054 D 53544 D Common Stock, par value $0.0001 per share 31483 I By Wife Stock Option (Right to Buy) 2.19 2013-12-16 4 M 0 4600 0.00 D 2022-10-02 Common Stock 4600 49810 D The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 5, 2013. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.08 per share to $21.395 per share, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This option is fully vested. /s/ Stephen Garbacz, attorney-in-fact 2013-12-17